Southeast Asia RA market to reach $1.44 billion by 2022, report

11 April 2017

The rheumatoid arthritis (RA) market in Southeast Asia, which covers South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam and Indonesia, is set to grow from $1.04 billion in 2015 to $1.44 billion by 2022, representing a compound annual growth rate of 4.7%,

According to business intelligence provider GBI Research’ s latest report, the entry of new therapies over the forecast period will stimulate market growth. Promising pipeline candidates include Eli Lilly (NYSE: LLY) and Incyte’s (Nasdaq: INCY) baricitinib, Regeneron’s (Nasdaq: REGN) sarilumab, GlaxoSmithKline (LSE: GSK) and Johnson & Johnson’s (NYSE: JNJ) sirukumab, Astellas’ (TYO: 4503) peficitinib and AbbVie’s (NYSE: ABBV) upadacitinib. Galapagos’ (Euronext: GLPG) filgotinib is in late-stage development, but will not be launched during the forecast period, as its Phase III trial completion date is in third-quarter 2020.

Competitive market

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK